To study biochemical effects of optimized product Ramipril 1.25 mg tablet with essential hypertension

ABSTRACT

Hypertension is one of the strongest modifiable risk factors for cardiovascular and kidney disease and has been identified as the leading risk factor for mortality. The reduction of blood pressure lower than 130/85 mmHg provides additional benefits regarding both protection of organs and cardiovascular mortality. Angiotensin converting enzyme inhibitors have been shown to block the activation of the renin-angiotensin system in the plasma as well as in the vascular wall. The objective of this double-blind, comparative study evaluating the biochemical effects of optimized Ramipril 1.25 mg tablet as monotherapy in adult patient with essential hypertension. Double-blind, comparative study. This study was conducted at the Department of Biochemistry, University of Karachi from January 2011 to August 2011. This was multicenter randomized, double-blind, comparative study. Patients were randomized to receive Ramipril [1.25 mg] once daily for 8 weeks and at the end of study biochemical evaluation was done. In the patients treated with optimized Ramipril 1.25 mg tablets showed antihypertensive property. No significant variations of blood glucose and different parameters of lipid profile were observed during the eight weeks of treatment. We can suggest that the high antihypertensive efficacy, good tolerability and no biochemical effects of the optimized Ramipril 1.25 mg [F-4] it is an excellent option for the treatment of hypertension in a wide range of hypertensive patients, with a high potential to reduce cardiovascular risks